Axon Enterprise (NASDAQ:AXON) Price Target Lowered to $625.00 at The Goldman Sachs Group

Axon Enterprise (NASDAQ:AXON) had its target price cut by The Goldman Sachs Group from $720.00 to $625.00 in a research report released on Wednesday morning,Benzinga reports. They currently have a buy rating on the biotechnology company’s stock.

A number of other equities research analysts also recently issued reports on the stock. Northcoast Research raised shares of Axon Enterprise from a “neutral” rating to a “buy” rating and set a $742.00 price objective for the company in a research report on Tuesday, January 6th. Piper Sandler cut their price objective on shares of Axon Enterprise from $753.00 to $690.00 and set an “overweight” rating for the company in a research report on Wednesday, February 25th. Needham & Company LLC cut their price objective on shares of Axon Enterprise from $870.00 to $600.00 and set a “buy” rating for the company in a research report on Friday, February 20th. Craig Hallum reissued a “buy” rating and set a $820.00 price objective on shares of Axon Enterprise in a research report on Wednesday, February 25th. Finally, Morgan Stanley dropped their target price on shares of Axon Enterprise from $713.00 to $675.00 and set an “overweight” rating for the company in a report on Wednesday, February 25th. Sixteen analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $755.88.

Axon Enterprise Trading Up 5.0%

Shares of AXON stock opened at $391.53 on Wednesday. Axon Enterprise has a 1 year low of $362.73 and a 1 year high of $885.91. The firm has a fifty day moving average price of $470.33 and a 200-day moving average price of $571.34. The company has a debt-to-equity ratio of 0.53, a current ratio of 2.53 and a quick ratio of 2.29. The company has a market cap of $31.48 billion, a price-to-earnings ratio of 257.59, a PEG ratio of 8.81 and a beta of 1.61.

Axon Enterprise (NASDAQ:AXON) last issued its quarterly earnings data on Tuesday, February 24th. The biotechnology company reported $2.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.60 by $0.55. Axon Enterprise had a net margin of 4.48% and a return on equity of 2.82%. The firm had revenue of $796.72 million during the quarter, compared to the consensus estimate of $755.29 million. During the same quarter in the previous year, the firm posted $2.08 EPS. The company’s revenue for the quarter was up 38.5% compared to the same quarter last year. As a group, equities analysts predict that Axon Enterprise will post 5.8 earnings per share for the current year.

Insider Buying and Selling

In related news, insider Isaiah Fields sold 2,000 shares of the company’s stock in a transaction on Friday, February 27th. The shares were sold at an average price of $535.01, for a total value of $1,070,020.00. Following the completion of the transaction, the insider owned 55,588 shares of the company’s stock, valued at approximately $29,740,135.88. This represents a 3.47% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Jeri Williams sold 157 shares of the company’s stock in a transaction on Tuesday, March 17th. The stock was sold at an average price of $490.00, for a total transaction of $76,930.00. Following the completion of the transaction, the director directly owned 1,159 shares of the company’s stock, valued at $567,910. This represents a 11.93% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 13,855 shares of company stock worth $7,109,828 in the last three months. Corporate insiders own 4.40% of the company’s stock.

Institutional Trading of Axon Enterprise

Several hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc. lifted its stake in Axon Enterprise by 0.6% in the 4th quarter. Vanguard Group Inc. now owns 9,367,224 shares of the biotechnology company’s stock worth $5,319,928,000 after purchasing an additional 53,060 shares in the last quarter. Geode Capital Management LLC lifted its stake in Axon Enterprise by 1.6% in the 4th quarter. Geode Capital Management LLC now owns 2,226,159 shares of the biotechnology company’s stock worth $1,265,657,000 after purchasing an additional 35,544 shares in the last quarter. Baillie Gifford & Co. lifted its stake in Axon Enterprise by 1,198.7% in the 4th quarter. Baillie Gifford & Co. now owns 1,642,578 shares of the biotechnology company’s stock worth $932,869,000 after purchasing an additional 1,516,099 shares in the last quarter. Sands Capital Management LLC lifted its stake in Axon Enterprise by 11.6% in the 4th quarter. Sands Capital Management LLC now owns 1,609,436 shares of the biotechnology company’s stock worth $914,047,000 after purchasing an additional 167,095 shares in the last quarter. Finally, Wellington Management Group LLP lifted its stake in Axon Enterprise by 326.9% in the 4th quarter. Wellington Management Group LLP now owns 1,539,738 shares of the biotechnology company’s stock worth $874,463,000 after purchasing an additional 1,179,038 shares in the last quarter. Hedge funds and other institutional investors own 79.08% of the company’s stock.

Axon Enterprise News Roundup

Here are the key news stories impacting Axon Enterprise this week:

• Positive Sentiment: Axon unveiled three AI-driven products (Axon Vision, expanded Axon Assistant, and Axon 911) designed to stitch live video, 911 data and field reporting into a single, real?time public?safety platform — a clear revenue/competitive narrative for investors. Axon AI tools press release
• Positive Sentiment: Multiple Wall Street analysts issued bullish notes during Axon Week (Goldman, Morgan Stanley and others), helping lift the stock as analysts emphasized AI-driven growth and reiterated buy ratings. Analyst optimism article
• Neutral Sentiment: Major firms trimmed price targets (Goldman Sachs cut $720?$625; TD Cowen cut $950?$825) but generally kept buy ratings — reduces near?term upside expectations while still signaling conviction in the long?term story. Price target coverage
• Negative Sentiment: Shares plunged ~10% earlier this week after a sudden selloff; coverage points to a mix of analyst target resets and new legal risks as catalysts for the drop. That volatility is still weighing on sentiment. Why shares traded lower
• Negative Sentiment: Axon hit a 52?week low amid the pullback and broader market weakness; investors should view this as both a risk signal and a potential entry point depending on conviction in AI rollout and legal outcomes. 52-week low report
• Negative Sentiment: Ongoing legal exposure (including a HQ dispute noted in coverage) is an overhang that analysts and investors flagged as part of the recent selloff; this could create further downside risk if developments are unfavorable. Legal risk coverage
• Negative Sentiment: Macro/geopolitical jitters (U.S.–Iran tensions) and a weaker tech/open market environment amplified the move lower earlier in the week, showing the stock remains sensitive to market risk-off episodes. Market headwinds article

Axon Enterprise Company Profile

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.